Rheumatology 2019;58:953–62.
doi:10.1093/rheumatology/key339
In Table 3, the entry in the ‘DVT/PE’ row, first column ‘Tofacitinib (JAK, JAK3)’ has been replaced with ‘NR’ as it states later in the paper that this is not reported.
. 2019 Jan 28;58(6):1122. doi: 10.1093/rheumatology/kez002
Clinical significance of Janus Kinase inhibitor selectivity
Ernest H Choy
1,✉
Ernest H Choy
1CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK
Find articles by Ernest H Choy
1CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK
✉
Correspondence to: Ernest H. Choy, CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park, Cardiff CF14 4XN, UK. E-mail: ChoyEH@cardiff.ac.uk
Issue date 2019 Jun.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC6532441 PMID: 30698756
This corrects the article "Clinical significance of Janus Kinase inhibitor selectivity" on page 953.